Probiotic Therapy of the Irritable Bowel Syndrome: Why Is the Evidence Still Poor and What Can Be Done About It?

Nazar Mazurak, Ellen Broelz, Martin Storr, and Paul Enck*

1SymbioGruppe GmbH, Herborn, Germany; 2Department of Psychosomatic Medicine, University Hospital Tübingen, Germany; and 3Center for Endoscopy, Starnberg, Germany

Background/Aims
Despite numerous randomized clinical trials and meta-analyses, there is no increased evidence for the efficacy of probiotics in the treatment of irritable bowel syndrome (IBS). We review this evidence, identify and analyse the reasons for this lack of evidence and propose methodological improvements for future studies.

Methods
Based on a literature search, we identified 56 papers that matched the purpose of our analyses. Twenty-seven studies used multi-species bacterial preparations and 29 used single-strain probiotics. They were analysed regarding patients included, treatment duration, probiotic dosage, and outcome measures.

Results
Trials in both groups suffered from heterogeneity with respect to probiotic concentration, duration of treatment, and other methodological issues (crossover design and underpowered studies). This heterogeneity did not allow the application of a meta-analytic approach and a systematic review was therefore performed instead. Multi-strain preparations combined 2 to 8 different bacterial subspecies, mostly lactobacilli or bifidobacteria, and used variable lengths of treatments. Overall, more than 50% of trials presented negative outcomes. The majority of the single-strain probiotic trials employing lactobacilli or Saccharomyces were negative, whereas trials employing bifidobacteria showed positive results.

Conclusions
The heterogeneity of the studies of probiotics in IBS questions the value of meta-analyses. The use of different bacterial strains and different mixtures of these strains, as well as different dosages, are the main contributors to this heterogeneity. Current data provides limited evidence for the efficacy of a small number of single-strain probiotics in IBS (mostly bifidobacteria) and
sound studies following strict trial guidelines (Food and Drug Administration and European Medicines Agency guidelines for clinical trials) are needed. We summarised and proposed some methodological issues for future studies in the field. *(J Neurogastroenterol Motil 2015;21:471-485)*

**Key Words**
Irritable bowel syndrome; Probiotics; Review

---

**Introduction**

“Probiotic” therapy—in contrast to antibiotic therapy—defines the use of single bacterial strains or combinations of bacterial strains to influence the commensal gut microbiota, despite the fact that the term “probiotic” was not used before the 1950s. Parker first established a definition in 1974. Fuller defined probiotic as a “living microbial food supplement” that improves the host by improving its intestinal bacterial balance. His definition is still valid today. This also resembles the position of the WHO/FAS (2001) which state that probiotics are living organisms that, when ingested in sufficient amounts, may be beneficial for the host. This definition avoids any speculation about the presumed mechanism of probiotics’ action. A 2014 update of the definition by the International Scientific Association for Probiotics and Prebiotics (ISAPP) confirmed the latter definition. In addition, bacterial yoghurt cultures usually consisting of *Lactobacillus delbrueckii* subsp. *bulgaricus* and *Streptococcus salivarius* subsp. *thermophilus*, which were not previously regarded as probiotics, are now included in this group.

The use of probiotics in the treatment of gastrointestinal (GI) tract disorders increased during the 1990s. Among the disorders that have been shown to benefit from probiotic treatment in placebo-controlled double-blinded studies are antibiotic-associated diarrhea, traveller’s diarrhea, rotavirus induced diarrhea, and *Clostridium difficile*-associated diarrhea. Beneficial effects have also been shown in diarrhea in children. Other bacterial strains showed efficacy in chronic constipation. Another potential indication was reported recently in the remission phase of ulcerative colitis, whereas randomized clinical trials (RCTs) in Crohn’s disease mostly revealed negative outcomes. Testing of probiotic therapy and targeting functional GI symptoms such as defecation problems (diarrhea and constipation) which are, however, not the predominant feature of diseases such as irritable bowel syndrome (IBS) were a significant step forward.

However, clinical trials prior to the formation of the international Rome consensus for functional bowel disorders in 1988 mostly lack credibility because a homogenous disease definition was lacking. The consequence was that in some trials, patients with or without abdominal pain in association with altered bowel habits were classified as IBS sufferers (or irritable colon, mucous colitis, or otherwise). In studies based on the Rome consensus IBS definition, efficacy was often based on improvement of individual symptoms including abdominal pain, diarrhea, and/or constipation.

A number of systematic reviews and meta-analyses analysed the efficacy of probiotics in the management of IBS and these publications are frequently mentioned and cited in consensus papers.

Over the years general assessments have remained rather similar, presuming an overall positive effect whilst claiming a lack of high-quality data: “Probiotics may improve symptoms of irritable bowel syndrome and can be used as supplement to standard therapy.” “While our analyses suggest that probiotic use may be associated with improvement in IBS symptoms compared to placebo, these results should be interpreted with caution given the methodological limitations of contributing studies. Probiotics warrant further study as a potential therapy for IBS.” “Probiotics may have a role in alleviating some of the symptoms of IBS, however further research should focus on the type, optimal dose of probiotics and the subgroups of patients who are likely to benefit the most.” “Six of the eight diseases (…irritable bowel syndrome...) showed positive significant effects. Across all diseases and probiotic species, positive significant effects of probiotics were observed for all age groups, single vs multiple species, and treatment lengths.”

Among these meta-analyses, the largest (including 35 trials) found a significant effect of probiotics on global IBS symptom rating for all 24 mono-strain preparations pooled; however neither lactobacilli nor bifidobacteria was effective when tested separately. There was also an overall benefit of the 15 combina-
tion trial; however, when specific combinations were tested, neither yielded a significant benefit over placebo. A significant effect of probiotics on individual IBS symptoms was only found for bloating and flatulence. A later meta-analysis covering data published between 2007 and 2013, which included only 14 RCTs, found probiotics to have a positive effect on abdominal pain only.28

The initial idea of our project was a meta-analysis on the efficacy of probiotics in the management of IBS. However, after the initial search and data extraction (see Methods below), we concluded that the current data did not allow a methodologically sound meta-analysis to be performed. We therefore performed a new literature search with a changed scope: to critically review the body of evidence and to identify and assess the reasons for poor evidence in the current literature, as reflected in recent meta-analyses. We also proposed ways to improve methods for studies in the future. Our new analysis was conducted in 4-steps: (1) literature search, (2) identification of systematic reviews and meta-analyses, (3) comparison of lists from Step 1 and 2, and lastly (4) sorting the final list according to specific criteria.

Methods

In our initial search early in 2014, we performed a PubMed literature search using the search terms "(probiotic OR prebiotic) AND (irritable-bowel-syndrome OR IBS OR functional-bowel-disorder) AND trial" to retrieve randomized trials comparing a probiotic or prebiotic to a control treatment in functional bowel disorders such as IBS.

The abstracts of retrieved papers were screened to match the following inclusion criteria:

1. The study including IBS patients according to pre-defined criteria (Manning, Kruis, and Rome);
2. The study only including adult patients;
3. The study design including a placebo arm;
4. The study being described as randomized;
5. The study with attempted blinding of patient assignment;
6. The study describing the probiotic or the probiotic bacterial strain in sufficient detail;
7. The study assessing either global IBS measures or single symptoms or QOL;
8. The full paper being available and written in English.

If only an abstract was available, we excluded the study. After exclusion of non-relevant studies, the remaining articles were screened for the following criteria:

1. Whether the study population was IBS, IBS-C or IBS-D, and IBS-M;
2. The number of patients included in the study;
3. Whether the probiotic was single-strain or multiple-strain;
4. In the case of multi-strain products, the strains included;
5. Whether it was a pharmacological or nutritional probiotic;
6. Whether the design was a parallel-group design or a cross-over design;
7. The duration of treatment.

All screenings were performed by 2 authors (E.B. and M.S.). In case of disagreement, a third author (N.M.) was consulted for a final decision. We also assessed the Jadad score for each selected study in order to assess the methodological quality of the clinical trials.

After the first review of the retrieved data and the decision to change the purpose and methodology of the project, we implemented a 4-step approach that helped us achieve our goals.

In Step 1 we performed a new literature search using the same key words — "(probiotic OR prebiotic) AND (irritable-bowel-syndrome OR IBS OR functional-bowel-disorder) AND trial" — which resulted in the generation of new literature set. The last update was performed on April 20, 2015. Retrieved papers were screened again using the inclusion and exclusion criteria described above.

In Step 2 we identified systematic reviews and meta-analyses in our literature search published between 2006 and 2015, which summarise the respective actual state of knowledge. They were reviewed for the included studies as well their major findings across all studies. A complete list of trials included in the reviewed meta-analyses and systematic reviews was generated independently from the literature list from Step 1.

In Step 3 we compared both retrieved literature lists from Step 1 and from Step 2 and identified papers included in one or both lists as well as those that were excluded by us, but which were included in one or more of the performed meta-analyses. For each discrepancy found, we discussed the respective paper among all authors to reach a final decision about it’s inclusion or exclusion using the same criteria described in Step 1.

Step 4: the final list of included studies was sorted according to the following criteria:

1. Single-strain or multi-strain probiotic;
2. Manufacturer of the preparation;
3. If multi-strain, which bacterial strains were present;
4. The dosage of each strain;
5. The form of preparation either as a nutritional product...
or a drug;
(6) If single-strain, the bacterial strain used, and at which dosage;
(7) Trial length and patient groups included;
(8) Study outcome as defined by the authors — positive or negative.

Based on our critical review of the current literature, we finally discussed the potential cornerstones of studies to investigate the efficacy of probiotics in IBS in the future.

Results

Step 1: Figure 1 shows the results of the literature search, last performed on April 20, 2015. After exclusion of systematic reviews and meta-analyses (n = 9), uncontrolled trials (n = 20), narrative reviews, editorial, letters and comments (n = 78), animal research (n = 2), studies of children and respective reviews (n = 10), non-English papers and studies (n = 8), and others (n = 8), 60 studies remained. Data published in abstract form only was not included.

Following a full-paper review, we excluded 8 further studies due to various reasons: only 1 study reported data from prebiotic treatment,29 1 study did not use a probiotic in a strict sense (no living bacteria),30 2 were microbial investigations of earlier studies,31,32 2 were single-blinded,33,34 and 2 were uncontrolled interventions.35,36 Based on hand-searches of the published meta-analyses, we added 3 more studies,37-39 resulting in a total of 55 articles.

Step 2: we identified 10 meta-analyses and systematic reviews (published between 2008 and 2015) related to probiotic trials in IBS,18-26,28 reporting a total of 44 RCTs with variable number of trials in each of them that increased over the years. One “systematic review” of complementary and alternative therapies in IBS was not comprehensive at all for IBS probiotic trials18; it included only 4 studies that were also analysed and discussed in all other reviews. Another review21 summarized previous systematic reviews and meta-analyses,19,22-24,40,41 but did not provide the full list of citations of papers and was therefore of no further help for the purpose of this review.

Step 3: we then compared the literature lists from Step 1 and Step 2 to identify the degree of overlap between each analysis. Of the 45 papers listed in Step 2, we excluded 14 for different reasons. Six citations were available as abstracts only42-47 and were thus of no value for our study. One of those41 has been published

Figure 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) scheme of retrieved literature.
Probiotics in IBS

Vol. 21, No. 4   October, 2015 (471-485)

475

Figure 2. Schematic overlap of 56 randomized clinical trials or probiotics in irritable bowel syndrome therapy, as they were included or excluded into 10 systematic reviews and meta-analyses published between 2008 and 2015. Numbers refer to the numbering in the reference list.

Except in 2 studies, all others pooled data and provided overall statistics and relative risk calculations. One performed a systematic review instead of a meta-analysis, but nevertheless mixed both groups.

Multi-strain Probiotics

The 27 included studies using multi-strain probiotics are listed in Table 1. Despite this common character, the studies were heterogeneous in many other aspects.

Study characteristics

The number of patients included ranged between 24 and 186 (median = 90). One study included patients with functional gastrointestinal disorders, ie, with diarrhea but not constipation and not necessarily suffering from abdominal pain. One was restricted to constipation predominant IBS (IBS-C) patients and 4 included only diarrhea predominant IBS (IBS-D) patients. All studies claimed the use of Rome (II or III) criteria, nevertheless, a more detailed description of the patient population (the number of IBS-D, IBS-C, and mixed IBS [IBS-M] patients) was lacking.

Treatment duration varied from 7 days to 6 months, thus not fulfilling Rome criteria for treatment duration in many cases, with the majority of studies assessing treatment results after 8 weeks. A common outcome-reporting period (4 weeks for example) was not available for comparison across all studies and neither were the primary nor the secondary outcome variables according to the FDA/EMA or Rome criteria in most studies.

Bacterial strain combinations

The largest heterogeneity was noted with respect to the bacterial strain combinations used (Table 2). Most of the multi-strain preparations were nutritional supplements from different suppliers worldwide. The same preparation (VSL.®) was used in only 3 studies. Up to 8 different bacterial strains are used in some preparations and the combinations are numerous, since in many cases subspecies of specific strains were used that are only available to (and eventually patented by) individual companies. Two studies were performed by the same research group with the same preparation.

The use of *Streptococcus thermophilus* and *Lactobacillus bulgaricus* as starting cultures for yoghurt production is occasionally noted; in the remaining cases it remains unclear whether these strains were included. They were not regarded as probiotics until 2014, when the ISAPP consented that they are probiotics by definition.
**Table 1. Multi-strain Randomized Placebo-controlled Probiotics Trials in Irritable Bowel Syndrome**

| Author            | Ref | IBS-type | N   | Dur | Global result on IBS symptoms |
|-------------------|-----|----------|-----|-----|-------------------------------|
| Shavakhi 2014     | 57  | All      | 132 | 2 wk| Negative                      |
| Jafari 2014       | 58  | All bloat| 108 | 4 wk| Positive                      |
| Lorenzo-Zúñiga 2014 | 59  | IBS-D    | 84  | 6 wk| Negative excl. QoL            |
| Sisson 2014       | 60  | All      | 186 | 12 wk| Positive                      |
| Ludidi 2014       | 61  | All      | 40  | 6 wk| Negative                      |
| Ko 2013           | 62  | IBS-D    | 53  | 8 wk| Negative                      |
| Begtrup 2013      | 63  | All      | 131 | 6 mo| Negative                      |
| Yoon 2013         | 64  | All      | 49  | 4 wk| Positive                      |
| Roberts 2013      | 65  | IBS-C    | 179 | 12 wk| Negative                      |
| Cui 2012          | 39  | All      | 60  | 4 wk| Positive                      |
| Min 2012          | 66  | All      | 130 | 7 day| Positive                      |
| Capello 2012      | 67  | All      | 64  | 4 wk| Negative excl. bloating       |
| Cha 2012          | 68  | IBS-D    | 50  | 10 wk| Positive                      |
| Michail 2011      | 69  | IBS-D    | 24  | 8 wk| Negative excl. satiety        |
| Hong 2011         | 70  | All      | 74  | 8 wk| Negative                      |
| Sondergaard 2011  | 71  | All      | 64  | 8 wk| Negative                      |
| Ringel-Kulka 2011 | 72  | FGD      | 60  | 8 wk| Positive                      |
| Simren 2010       | 48  | All      | 74  | 8 wk| Negative excl. week 1         |
| Hong 2009         | 38  | All      | 70  | 8 wk| Positive                      |
| Williams 2009     | 73  | All      | 32  | 8 wk| Positive                      |
| Kajander 2008     | 74  | All      | 86  | 5 mo| Positive                      |
| Drouault 2008     | 75  | All      | 100 | 4 wk| Negative                      |
| Kajander 2005     | 76  | All      | 103 | 6 mo| Positive                      |
| Kim 2005          | 77  | All      | 48  | 4-8 wk| Negative excl. bloating       |
| Bittner 2005      | 78  | All      | 25  | 2 wk| Positive                      |
| Saggioro 2004     | 79  | All      | 50  | 4 wk| Positive                      |
| Kim 2003          | 80  | IBS-D    | 25  | 8 wk| Negative                      |

Ref, number in reference list; N, number of patients in study; Dur, duration of treatment; IBS, irritable bowel syndrome; bloat, bloating; IBS-D, diarrhea predominant IBS; exc, excluding/except; QoL, quality of life; IBS-C, constipation predominant IBS; FGD, functional gastrointestinal disease.

While some strains (such as *Lactobacillus acidophilus*) are used in almost all studies, many if not most of the strains are used exclusively in a few combinations. The table lists only bacterial strains that were used at least twice among the included studies.

The concentration of bacteria in these studies was not always reported\(^{57,78}\) and varied substantially, ranging from \(10^8\) (Shavakhi et al\(^{57}\)) to \(10^{11}\) (Michail et al\(^{69}\)), providing that the concentrations listed in the papers are correct and that (specifically for dairy products) the cooling chain had not been disrupted. Only one study compared a high dose (\(3 \times 10^{10}\) colony forming unit [cfu]) with a low dose (\(6 \times 10^9\) cfu) and found both equally ineffective compared to placebo.\(^{59}\)

Due to the heterogeneity of the different probiotic compositions, it appeared inappropriate to perform a meta-analysis; except for the 3 VLS#3 studies which have been reported to provide no benefit over placebo in IBS.\(^{50}\)

**Global outcome**

Most studies included here reported their outcome in global terms. We used these explicit summaries of the efficacy of the respective probiotic treatment to retrieve a globally rated “positive” or “negative” IBS treatment outcome. However, we are aware of the fact that this may be biased by the respective authors that tend to underestimate or undervalue negative results, for instance in comparison to registered trial reports.\(^{81,82}\)

We found that 14 of the 27 studies reported negative outcome on global symptoms, however individual symptoms (bloating “exc satiety”) were occasionally reported as being responsive to treatment. Quality of life (QoL) improved in one study but symptomatic improvement was not different from placebo.\(^{59}\) Thirteen
### Table 2. Composition of Multi-strain Probiotic Preparations

| Author          | Ref  | Company       | Ref, number in reference list | S. thermophilus | L. bulgaricus | Dosage (cfu) | L. casei | L. salivarius | L. lactis | L. acidophilus | L. rhamnus | L. plantarum | L. longum | B. lactis | B. brevis | B. lounum | B. bifidum | B. infantis |
|-----------------|------|---------------|-------------------------------|-----------------|---------------|--------------|-----------|--------------|-----------|---------------|-----------|--------------|-----------|-----------|----------|----------|----------|-----------|
| Shavakhi 2014   | 57   | Protexin      |                               |                 |               | 1 × 10⁸      |           |              |           |               |           |             |           |           |          |          |          |           |
| Jafari 2014     | 58   | Pr-Biotech    |                               |                 |               | 4 × 10⁹      |           |              |           |               |           |             |           |           |          |          |          |           |
| Lorenzo-Zúñiga 2014 | 59  | AB-Biotics    |                               |                 |               | 3 × 10¹⁰     |           |              |           |               |           |             |           |           |          |          |          |           |
| Sisson 2014     | 60   | Symprove      |                               |                 |               | 1 × 10¹⁰     |           |              |           |               |           |             |           |           |          |          |          |           |
| Ludidi 2014     | 61   | Wincolve      |                               |                 |               | 5 × 10⁹      |           |              |           |               |           |             |           |           |          |          |          |           |
| Ko 2013         | 62   | Cell Biotech  |                               |                 |               | 5 × 10⁹      |           |              |           |               |           |             |           |           |          |          |          |           |
| Beitrups 2013   | 63   | Arla          |                               |                 |               | 1.3 × 10¹⁰   |           |              |           |               |           |             |           |           |          |          |          |           |
| Yoon 2013       | 64   | Cell Biotech  |                               |                 |               | 5 × 10⁹      |           |              |           |               |           |             |           |           |          |          |          |           |
| Roberts 2013    | 65   | Danone        |                               |                 |               | 1.25 × 10¹⁰  |           |              |           |               |           |             |           |           |          |          |          |           |
| Cui 2012        | 39   | Sine Pharm    |                               |                 |               | NR           |           |              |           |               |           |             |           |           |          |          |          |           |
| Min 2012        | 66   | Namyang       |                               |                 |               | 1 × 10¹¹     |           |              |           |               |           |             |           |           |          |          |          |           |
| Capello 2012    | 67   | CaDi Group    |                               |                 |               | 1.4 × 10¹⁰   |           |              |           |               |           |             |           |           |          |          |          |           |
| Cha 2012        | 68   | Cell Biotech  |                               |                 |               | 1 × 10¹⁰     |           |              |           |               |           |             |           |           |          |          |          |           |
| Michail 2011    | 69   | VSL.#3        |                               |                 |               | 9 × 10¹¹     |           |              |           |               |           |             |           |           |          |          |          |           |
| Hong 2011       | 70   | Yakult        |                               |                 |               | 4 × 10⁹      |           |              |           |               |           |             |           |           |          |          |          |           |
| Sondergaard 2011| 71   | Arla          |                               |                 |               | 7.5 × 10¹⁰   |           |              |           |               |           |             |           |           |          |          |          |           |
| Ringel-Kulka 2011| 72  | NR            |                               |                 |               | 1 × 10¹¹     |           |              |           |               |           |             |           |           |          |          |          |           |
| Simren 2010     | 48   | Cultura       |                               |                 |               | 1 × 10¹⁰     |           |              |           |               |           |             |           |           |          |          |          |           |
| Hong 2009       | 38   | Bifido Co     |                               |                 |               | 2 × 10¹⁰     |           |              |           |               |           |             |           |           |          |          |          |           |
| Williams 2009   | 73   | Cuhech        |                               |                 |               | 2.5 × 10⁹    |           |              |           |               |           |             |           |           |          |          |          |           |
| Kajander 2008   | 74   | Valio Ltd     |                               |                 |               | 4.8 × 10⁹    |           |              |           |               |           |             |           |           |          |          |          |           |
| Druwaut 2008    | 75   | NR            |                               |                 |               | 1 × 10¹⁰     |           |              |           |               |           |             |           |           |          |          |          |           |
| Kajander 2005   | 76   | Valio Ltd     |                               |                 |               | 8.9 × 10⁹    |           |              |           |               |           |             |           |           |          |          |          |           |
| Kim 2005        | 77   | VSL.#3        |                               |                 |               | 4.5 × 10¹¹   |           |              |           |               |           |             |           |           |          |          |          |           |
| Bittriner 2005  | 78   | Prescript     |                               |                 |               | NR           |           |              |           |               |           |             |           |           |          |          |          |           |
| Saggiotto 2004  | 79   | Frohial       |                               |                 |               | 1 × 10¹⁰     |           |              |           |               |           |             |           |           |          |          |          |           |
| Kim 2003        | 80   | VSL.#3        |                               |                 |               | 4.5 × 10¹¹   |           |              |           |               |           |             |           |           |          |          |          |           |

*Indicates dosage included *Streptococcus thermophilus* and *Lactobacillus bulgaricus.*

Ref, number in reference list cfu, colony-forming units; NR, not reported.

An "x" indicated use of this bacteria, an "x x" indicates use of 2 different bacteria of the same strain.
Table 3. Randomized Clinical Trials With Mono-strain Probiotics in Irritable Bowel Syndrome

| Author              | Ref | Strain             | Drug or Nutr | Daily dosage (cfu) | IBS-type | N  | IBS def | Therapy duration | Results                  |
|---------------------|-----|--------------------|---------------|-------------------|----------|----|---------|------------------|--------------------------|
| de Chambrun 2014    | 83  | *S. cerevisiae*    | Nutri 4 × 10⁹  | All               | IBS-D    | 179| R III   | 8 wk             | Negative exc pain        |
| Abbas 2014          | 84  | *S. boulardi*      | NR 750 mg     | IBS-D             | 72       | R III| 6 wk   |                 | Negative exc for QoL      |
| Stevenson 2014      | 85  | *L. plantagin*     | Drug 1 × 10⁴  | IBS-D/C/D         | 81       | R II | 8 wk   |                 | Negative                 |
| Rhoga 2014          | 86  | Bac coag + preb    | Nutri 4.5 × 10⁸ | All               | 85       | R II | 12 wk |                 | Positive                 |
| Urgesi 2014         | 87  | Bac coag + simet   | Drug NR       | All               | 52       | R III| 4 wk   |                 | Positive                 |
| Charbonneau 2013    | 88  | *B. infantes*      | NR 1 × 10⁹    | All               | 76       | Rome| 8 wk   |                 | Negative                 |
| Ducrotte 2012       | 89  | *L. plantagin*     | Drug 1 × 10⁹  | All               | 214      | R III| 4 wk   |                 | Positive                 |
| Munakami 2012       | 90  | *L. brevi*         | Drug 1 × 10⁹  | All               | 35       | R III| 2 × 4 wk|               | Negative                 |
| Dapoigny 2012       | 91  | *L. casei*         | Drug 6 × 10³  | All               | 50       | R III| 4 wk   |                 | Negative                 |
| Knus 2012           | 92  | *E. coli Nissle*   | Drug 5 × 10⁰  | All               | 120      | R II | 12 wk |                 | Negative exc PI-IBS      |
| Kabir 2011          | 93  | *S. boulardi*      | NR 500 mg     | All               | 70       | R II | 4 wk   |                 | Negative                 |
| Guglielmetti 2011   | 94  | *B. bifidum*       | Nutri 1 × 10⁹ | All               | 122      | R III| 6 wk   |                 | Positive                 |
| Choi 2011           | 95  | *S. boulardi*      | Drug 8 × 10¹⁰ | IBD-D/M           | 67       | R II | 4 wk   |                 | Negative exc for QoL      |
| Ligaarden 2010      | 52  | *L. plantagin*     | Drug 1 × 10⁹  | All               | 16       | R II | 2 × 3 wk|               | Negative                 |
| Dolin 2009          | 96  | *B. coagulans*     | Drug 2 × 10⁹  | IBS-D             | 55       | R III| 8 wk   |                 | Positive                 |
| Hun 2009            | 97  | *B. coagulans*     | Drug 8 × 10⁹  | IBS-D             | 44       | R II | 8 wk   |                 | Positive                 |
| Enck 2009           | 98  | *E. coli*          | Drug > 1 × 10⁶ | All               | 298      | Pre R| 8 wk   |                 | Positive                 |
| Agarwal 2008        | 99  | *L. lactis*        | Nutri 1.25 × 10⁶ | IBS-C          | 41       | R III| 4 wk   |                 | Positive                 |
| Sinn 2008           | 100 | *L. acidophilus*   | Nutri 2 × 10⁶  | All               | 40       | R III| 4 wk   |                 | Positive                 |
| Guyonnnet 2007      | 101 | *B. animalis*      | Nutri 2.5 × 10⁹ | IBS-C          | 274      | R II | 6 wk   |                 | Negative exc for QoL      |
| Whorwell 2006       | 102 | *B. infantes*      | Nutri 1 × 10⁹ | All (female)      | 362      | R II | 4 wk   |                 | Positive                 |
| Niv 2005            | 103 | *L. reuteri*       | Nutri 2 × 10⁹  | All               | 54       | R II | 6 mo   |                 | Negative                 |
| O`Mahorny 2005      | 104 | *Bifidobacterium* vs *Lactobacillus* | Drug 1 × 10⁹ | All               | 77       | R II | 8 wk   |                 | Negative for *Lactobacillus* |
| Sen 2002            | 105 | *L. plantagin*     | Nutri 6.25 × 10⁹ | All               | 12       | Rome| 2 × 4 wk|               | Negative                 |
| Niedrich 2001       | 106 | *L. plantagin*     | Nutri 2 × 10⁹  | All               | 40       | Pre R| 4 wk   |                 | Positive                 |
| O`Sullivan 2000     | 107 | *L. rhamnosus*     | Drug 1 × 10⁹  | All               | 24       | Rome| 2 × 8  |                 | Negative                 |
| Nobaeck 2000        | 108 | *L. plantagin*     | Nutri 2 × 10⁹  | All               | 60       | R I  | 4 wk   |                 | Negative exc bloating     |
| Halpen 1996         | 56  | *L. acidophilus*   | Nutri 2 × 10⁹  | All               | 18       | Pre R| 2 × 6 wk|               | Positive                 |
| Gade 1989           | 37  | *S. faecalis*      | Nutri 8 × 10⁶  | All               | 44       | Pre R| 2 wk   |                 | Positive                 |

Ref, number in reference list; Nutr, nutritional supplement; cfu, colony forming units; IBS, irritable bowel syndrome; N, number of patients in study; R I/II/III, Rome definition of IBS; NR, not reported; 2 × 3 or 2 × 4 or 2 × 6, 2 consecutive treatment periods of 3, 4, or 6 weeks (in a cross-over design) exc, except; IBS-D, diarrhea predominant IBS; IBS-C, constipation predominant IBS; IBS-M, mixed IBS; QoL, quality of life; PI-IBS, postinfectious IBS; S., *Saccharomyces*; L., *Lactobacillus*; B., *Bifidobacterium*; St., *Streptococcus*; coag + preb, *Bacillus coagulans* + Prebiotikum; coag + simet, *Bacillus coagulans* + simethicone. Pre R was used in a case when other than Rome criteria (eg, Manning) were used to define IBS or the type of criteria was not reported in the paper ("Pre R?").
studies were positive on global symptom reports. While the size of the study populations has increased, this did not affect the (positive or negative) outcome of the studies, as more patients were included in the studies reporting negative outcomes than in the studies with positive outcomes (Table 1).

In summary, the balance of positive and negative studies indicates an arbitrary and random result rather than an effective outcome of treatment attempts in IBS using multi-strain probiotics. This contrasts with the summary of Ford et al\textsuperscript[26] that found an overall positive effect of multi-strain probiotics in IBS when all included studies were pooled, but not of individual combinations.

**Single-strain Probiotics**

**Study characteristics**

The 29 single-strain probiotic intervention studies exhibited a large variability with respect to various design features, as shown illustrated in Table 3.\textsuperscript[5,2,32,56,83-108] Four studies employed a cross-over design,\textsuperscript[52,56,90,105] which is frequently used for motivational purposes (patients are easier to recruit when they are offered an effective treatment, at least for a part of the trial). However, they are difficult to evaluate since the assumption that the data in both periods is equal and can be merged may be distorted by unblinding and conditioning effects.\textsuperscript[109]

Compared to multi-strain studies, more investigations (15/29) were limited to 4 weeks (or \(2 \times 4\) weeks in a cross-over design) and some extended up to 8 weeks or beyond (11/29). Similarly, the range of included IBS patients ranged from 12 to 362. Two trials included IBS-C,\textsuperscript[99,101] and 3 trials only IBS-D patients,\textsuperscript[84,96,97] while 2 studies stratified the patients into IBS-C and IBS-D\textsuperscript[97] or into IBS-D and IBS-M.\textsuperscript[95] Only one study addressed another subgroup of patients who may benefit from probiotics: patients with post-infectious IBS.\textsuperscript[110] Unfortunately, the researchers did this post-hoc rather than prospectively (see below).\textsuperscript[92]

Inclusion criteria also varied. Four studies did not specify which criteria were used defining IBS patients,\textsuperscript[56,88,105,107] which may indicate that data was collected before Rome criteria became effective and in 2 studies, this was expressed in the article (pre-Rome).\textsuperscript[98,106] Whilst male patients were included, females were dominant in all trials; one study exclusively recruited female patients.\textsuperscript[102]

**Bacterial strains**

With respect to the bacterial strains studied, the heterogeneity continued: 6 studies used *Lactobacillus plantarum*,\textsuperscript[52,85,89,105,106,108] however of different origin and subspecies; some were nutritional supplements and some were developed as drugs. Other lactobacilli strains were used only in single trials, such as *Lactobacillus brevis*,\textsuperscript[90] *L. acidophilus*,\textsuperscript[56,100] *Lactobacillus reuteri*,\textsuperscript[103] *Lactobacillus rhamnosus* GG,\textsuperscript[100] and *Lactobacillus casei* (CLR35).\textsuperscript[91]

A similar picture emerged with bifidobacteria. Individual trials have used *Bifidobacterium bifidum* (MIMB675),\textsuperscript[94] *Bifidobacterium lactis*,\textsuperscript[90] *Bifidobacterium animalis*,\textsuperscript[101] and *Bifidobacterium infantis*.\textsuperscript[88,102]

A number of studies have used the yeast *Saccharomyces boulardii*,\textsuperscript[94,95,95] however, it is unclear whether they used the same strain, produced and/or distributed by different companies. A novel study used a variant, *Saccharomyces cerevisiae*.\textsuperscript[83] Four studies investigated the efficacy of *Bacillus coagulans*.\textsuperscript[96,97,96,97] again from different companies, in 2 instances combined with a prebiotic\textsuperscript[86] or simethicone,\textsuperscript[87] which makes direct comparison difficult. One study used a *Streptococcus faecium* strain\textsuperscript[37] and 2 used different *Escherichia coli* strains, *E. coli Nissle*,\textsuperscript[92] and *E. coli*.\textsuperscript[98]

Only one study compared 2 completely different probiotics and found that *B. infantis* was superior to *Lactobacillus salivarius*, which was not superior to placebo.\textsuperscript[104] One study\textsuperscript[104] compared 3 different putatively effective doses (\(1 \times 10^6\), \(1 \times 10^8\), and \(1 \times 10^{10}\) cfu) of a single strain, *B. infantis* and found the lowest and the highest dose to be ineffective. The authors claimed a technical issue as being responsible for the inefficacy of the highest dose (\(1 \times 10^{10}\) cfu).

As with multi-strain probiotics, the concentration of bacteria in these studies was either not reported,\textsuperscript[94,97,93] or the daily dosage varied by almost a factor of 1000, ranging from \(1 \times 10^6\) (Whorwell et al\textsuperscript[102]) to \(8 \times 10^{11}\) (Choi et al\textsuperscript[95]).

**Global outcome**

Again, we used the authors’ evaluation of their results and separated positive from negative studies. Studies that noted an improvement of QoL, without changes in abdominal symptoms (pain, stool frequency, and bloating),\textsuperscript[94,95,101] were labelled as “negative except QoL,” since it is against all recommendations (Rome criteria and FDA/EMA) to use QoL as a primary end-point in IBS treatment studies.

Three more studies were identified as negative, contrary to the evaluation of the respective authors: one found a significant effect on abdominal pain, but not on other IBS symptoms. Upon visual inspection of the data (ibid., see Figure 3 in Pineton de Chambrun et al\textsuperscript[83]), the effect occurred during weeks 6 to 8 with a sudden change in pain severity, mimicking a “recruitment bias”

Vol. 21, No. 4 October, 2015 (471-485)
of unknown origin; however, it lacks any rational discussion and explanation. A similarly surprising and unexplained change occurred in the responder data of another study (ibid., see Figure 2 in Kruis et al),101 during weeks 9 to 12, which may explain for the post-hoc significance in a subgroup of patients with post-infectious IBS. Consequently, less evidence was produced with inhomogeneous placebo rates have dropped and efficacy of drugs over placebo has increased,114 the development of probiotics has not followed the same trend. One reason for this might be that, investments in clinical research and trials are still the exception rather than the rule for the nutritional (dairy) industry, not least because of lower profit rates and higher turn-around of investments into marketing of products.

Instead of rigorously questioning the value of previously tested probiotics in IBS, we finally attempted to outline the requirements for future trials to overcome these limitations. Many of these are already clinical standards that have been set during the last 25 years in GI drug development, by drug companies, approval authorities, and expert consensus parties. These have not been adopted yet by the nutritional industry that is responsible for most of the compounds that have been put to the market. However, clearly there cannot be different standards for drug and nutrient testing, and the future common policy of EMA and European Food Safety Authority in Europe115 has underlined this.

How to Study Efficacy of Probiotics in Irritable Bowel Syndrome

Since GI health claims for probiotics have to assess efficacy with respect to patients with functional bowel disorders of IBS-type,111 they have to be measured with standards of drug testing in the same area, ie, according to FDA and EMA rules112,113 and the consensus of the gastroenterology community.17 The following provides a summary of putative paradigms to guide future trials.

Discussion

Our systematic review of 56 published RCTs of probiotics in IBS and of 10 systematic reviews and meta-analyses, including most of these trials, identified major flaws in the RCTs, obscuring the evidence for the efficacy of probiotics as a treatment option in IBS. Consequently, less evidence was produced with increasing numbers of RCTs added to meta-analyses. The latest and largest of these meta-analyses26 concluded that while across all studies moderate evidence exists for efficacy of probiotics in general (though restricted to single-strain preparations) on global symptoms, neither individual bacterial strain reached a sufficient level of evidence, nor are individual core IBS symptoms (except bloating) effectively treated by any of the tested bacteria. Multi-strain probiotics appear to be of no value at all. Narrative reviews on the efficacy of probiotic treatment in IBS usually follow these systematic reviews and meta-analyses.111

In an attempt to understand why the picture has not improved but has rather developed into the opposite in recent years, we analysed all available studies for homogeneity in the applied drugs (or food supplements), in design and trial features and global outcomes and found that heterogeneity rather than homogeneity has increased over the years. Patient recruitment and selection especially, treatment duration, probiotic dosages and the choice of primary and secondary endpoints of the study have not followed the same route that pharmacology of GI drugs have paved through the FDA,112 EMA,113 and international consensus parties such as the Rome group.17 Whilst in GI pharmacology placebo rates have dropped and efficacy of drugs over placebo has increased,114 the development of probiotics has not followed the same trend. One reason for this might be that, investments in clinical research and trials are still the exception rather than the rule for the nutritional (dairy) industry, not least because of lower profit rates and higher turn-around of investments into marketing of products.

Nazar Mazurak, et al
First and foremost, any clinical study should be registered and it should be registered before the study start and not after the data evaluation. Only 6 of the 27 multi-strain probiotic studies were registered. Even more surprisingly, only 3 of the 29 studies with single-strain probiotics were registered despite the fact that the single-strain probiotics were used not as nutritional supplement, but as drug by the majority. Registration prevents (silent) deviations from the proposed protocol and statistical evaluation strategy and diminishes doubts as to whether the reported efficacy data was a re-interpretation of missing efficacy on the primary endpoints chosen (see above).

Secondly, the study would need to be adequately powered. As we have repeatedly discussed, studies with samples size lower than 100 patients are at increased risk of producing high and variable placebo response rates and therefore would need strong effects on the primary study endpoint to achieve significance. However, this cannot be expected with nutritional interventions (even when provided as approved drugs) which is confounded by the variability of daily nutrition including consumption of pre- and probiotics. In this respect, 19 of the 27 multi-strain and 21 of the 29 single-strain probiotic studies had a priori low chance of finding significant effects; however, to our knowledge only a few were based on a power calculation.

Thirdly, a probiotic study in IBS patients would preferentially not use a cross-over design; such designs have almost completely been abandoned in gastrointestinal pharmacology and elsewhere for obvious reasons. They carry the risk of unblinding, of cross-over effects when wash-out periods are too short, and of conditioning effects in the second (placebo) phase when the initial treatment is the probiotic. Consequently, the statistical evaluation should be restricted to the first treatment phase; however, these studies are usually not powered for such “quasi parallel design.” Only 4 of the single-strain studies and none of the others installed a cross-over design.

Furthermore, inclusion and exclusion criteria should closely follow the EMA and FDA guidelines for clinical trials in IBS, including the definition of minimal severity for inclusion, global primary endpoints, and adequate secondary endpoints (pain, bloating, and a clinically meaningful responder definition). It should incorporate at least 8 weeks of treatment, an adequate follow-up interval and restriction to one of the different IBS subtypes. Documentation of nutritional habits as well as stool and pain diaries should be mandatory.

Finally, either a single-strain probiotic should be tested against placebo, or 2 different probiotics in a comparative effectiveness research design and the compounds chosen should be based on the available evidence. This excludes multi-strain probiotics, dairy products that require maintenance of the cooling chain and probiotics which have not been able to demonstrate superiority over placebo despite frequent trials, as documented in our list above. Comparative effectiveness research trials need larger samples (for demonstration of non-inferiority and the choice of the comparator is essential. A 3-arm trial (such as O’Mahony et al) testing 2 different probiotics against placebo is certainly an elegant alternative. Comparing probiotic treatment to other dietary or non-dietary therapies (prebiotics and simethicone) or adding probiotics to other treatments (acupuncture) may help in recruiting patients but does not support the search for evidence.

We are aware of the limitations of our own analysis. While we included as many published trials as possible into this systematic review, we excluded trials reported as abstracts only and those not published in English. For a meta-analysis of overall efficacy, this may create a publication bias: however, for a critical review of methodological flaws this may not be as relevant since detailed data needed for critical analyses is usually not included into congress abstracts. We also ignored differences in primary endpoints (and their statistical characteristics, continuous or binary) reported in these studies and referred to reported overall efficacy data as “true” — assuming that the authors have reported the best evidence they could gain from their own data, irrespective of what the initial evaluation plan was. Otherwise, the overall evidence may have been even poorer. Finally, since most of the multi-strain preparations were nutritional supplements from different suppliers worldwide, the same product may have been available in different countries under different brand names with different labelling and approved for different indications due to differences in national regulations for approval of nutritional supplements. We were not able to resolve this issue.

When evaluating the efficacy of the FODMAP diet in IBS on behalf of the Rome Foundation, Yao et al thoroughly discussed the methodological difficulties of dietary trials, with an emphasis on functional bowel disorders. Most importantly, dietary intervention trials need to address the collinearity between food, nutrients, and bioactive components which could obscure the relationship between food and their effects in the gut. The authors provided recommendations for such trials, ranging from assessment and documentation of baseline nutrients intake, via adequate masking of study food, to the design of adequate sham controls; however, the authors insist that for food trials, the
randomized, double-blind and placebo-controlled study remain as the gold standard.

In summary we conclude, that the heterogeneity of the studies of probiotics in IBS questions the value of meta-analyses. The use of different bacterial strains and different mixtures of these strains, as well as different dosages, are the main contributors to this heterogeneity. Current data provides limited evidence for the efficacy of a small number of single-strain probiotics in IBS (mostly bifidobacteria) and sound studies following strict trial guidelines (FDA and EMA guidelines for clinical trials) are needed.

References

1. Kneifel W, Salminen S. Probiotics and health claims. Blackwell Publishing Ltd, 2011.
2. Bested AC, Logan AC, Selhub EM. Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part I - autointoxication revisited. Gut Pathog 2013;5:5.
3. Parker RB. Probiotics, the other half of the antibiotic story. Anim Nutr Health 1974;29:4-8.
4. Fuller R. Probiotics in man and animals. J Appl Bacteriol 1989;66:365-378.
5. Food and Agriculture Organisation WHO. Evaluation of health and nutritional properties of probiotics in food, including powder milk with live lactic acid bacteria. FAO & WHO Expert Consultation Report. Geneva, 2001.
6. Hill C, Guarner F, Reid G, et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol 2014;11:506-514.
7. Surawicz CM, Elmer GW, Spelman P, McFarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhea by *Saccharomyces boulardii*: a prospective study. Gastroenterology 1989; 96:981-988.
8. Oksanen PJ, Salminen S, Saxelin M, et al. Prevention of travellers’ diarrhoea by *Lactobacillus GG*. Ann Med 1990;22:53-56.
9. Isolauri E, Kaila M, Mylkanen H, Lang WH, Salminen S. Oral bacteriotherapy for viral gastroenteritis. Dig Dis Sci 1994;39:2595-2600.
10. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. JAMA 1994;271:1913-1918.
11. Isolauri E, Juntunen M, Rautanen T, Sillanaukee P, Koivula T. A human *Lactobacillus* strain (*Lactobacillus casei* sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 1991;88:90-97.
12. Kim SF, Choi SC, Park KS, et al. Change of fecal flora and effectiveness of the short-term VSL. #3 probiotic treatment in patients with functional constipation. J Neurogastroenterol Motil 2015;21:111-120.
13. Kruis W, Schutz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral *Escherichia coli* preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 1997;11:853-858.
14. Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelincic KA, DuPont AW. Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol 2014;7:473-487.
15. Thompson WG. The road torome. Gastroenterology 2006;130:1532-1536.
16. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978;2:653-654.
17. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006;130:1480-1491.
18. Hussain Z, Quigley EM. Systematic review: complementary and alternative medicine in the irritable bowel syndrome. Aliment Pharmacol Ther 2006;23:465-471.
19. McFarland LV, Dublin S. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J Gastroenterol 2008;14:2650-2661.
20. Nikfar S, Rahimi R, Rahimi F, Derakhshani S, Abdollahi M. Efficacy of probiotics in irritable bowel syndrome: a meta-analysis of randomized, controlled trials. Dis Colon Rectum 2008;51:1775-1780.
21. Whelan K. Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews. Curr Opin Clin Nutr Metab Care 2011;14:581-587.
22. Brenner DM, Moeller MJ, Chey WD, Schoenfeld PS. The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review. Am J Gastroenterol 2009;104:1033-1049.
23. Hoveyda N, Heneghan C, Mahanti KR, Perera R, Roberts N, Glassiou P. A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome. BMC Gastroenterol 2009;9:15.
24. Moayyedi P, Ford AC, Talley NJ, et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 2010;59:325-332.
25. Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One 2012;7:e34938.
26. Ford AC, Quigley EM, Lacy BE, et al. Efficacy of probiotics, prebiotics, and synbiotics in irritable bowel syndrome: a systematic review and meta-analysis. Am J Gastroenterol 2014;109:1547-1561.
27. Hungin AP, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice—an evidence-based international guide. Aliment Pharmacol Ther 2013;38:864-886.
28. Didari T, Mozaffari S, Nikfar S, Abdollahi M. Effectiveness of probiotics in irritable bowel syndrome: updated systematic review with meta-analysis. World J Gastroenterol 2015;21:3072-3084.
29. Silk DB, Davis A, Vulevic J, Tzortzis G, Gibson GR. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment Pharmacol Ther 2009;29:508-518.
Enterococcus faecalis (DSM 16440) for treatment of the irritable bowel syndrome—a randomized controlled trial with primary care physicians. Neurogastroenterol Motil 2008;20:1103-1109.

31. Kajander K, Krogius-Kurikka L, Rinttilä T, Karjalainen H, Palva A, Korpela R. Effects of multispecies probiotic supplementation on intestinal microbiota in irritable bowel syndrome. Aliment Pharmacol Ther 2007;26:463-473.

32. Farup PG, Jacobsen M, Ligiarden SC, Rudi K. Probiotics, symptoms, and gut microbiota: what are the relations? A randomized controlled trial in subjects with irritable bowel syndrome. Gastroenterol Res Pract 2012;2012:214102.

33. Zeng J, Li YQ, Zuo XL, Zhen YB, Yang J, Liu CH. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2008;28:994-1002.

34. Aminimani B, Nikfam S, Alboji M, et al. Probiotic vs. placebo in irritable bowel syndrome: a randomized controlled trial. Middle East J Dig Dis 2013;5:98-102.

35. Beljìdi P, Vitali B, Swennen E, Bazzocchi G, Matteuzzi D. Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea. Res Microbiol 2001;152:735-741.

36. Pedersen N, Andersen NN, Végh Z, et al. Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome. World J Gastroenterol 2014;20:16215-16226.

37. Gade J, Thrøn P. Paraghurt for patients with irritable bowel syndrome. A controlled clinical investigation from general practice. Scand J Prim Health Care 1989;7:23-26.

38. Hong KS, Kang HW, Im JP, et al. Effect of probiotics on symptoms in Korean adults with irritable bowel syndrome. Gut Liver 2009;3:101-107.

39. Cui S, Hu Y. Multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Int J Clin Exp Med 2012;5:238-244.

40. Irritable bowel syndrome in adults: diagnosis and management of irritable bowel syndrome in primary care. National Collaborating Centre for Nursing and Supportive Care: National Institute for Health and Clinical Excellence, 2008.

41. Huertas-Ceballos AA, Logan S, Bennett C, Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev 2009;CD003019.

42. Simren M, Syrous A, Lindh A, Abrahamsson H. Effects of Lactobacillus plantarum 299v on symptoms and rectal sensitivity in patients with irritable bowel syndrome (IBS)—a randomized, double-blind controlled trial. Gastroenterology 2006;130:A600.

43. Simren M, Lindh A, Sammelsson L, et al. Effect of yoghurt containing three probiotic bacteria in patients with irritable bowel syndrome (IBS)—a randomized, double-blind, controlled trial. Gastroenterology 2007;132:A210.

44. Euck P, Menke G, Zimmermann K, Martens U, Klosterhalfen S. Effective probiotic therapy of the irritable bowel syndrome (IBS): a multi-center clinical trial with primary care physicians. Gastroenterology 2007;132(suppl 2):A79.

45. Kim YG, Moon JT, Lee KM, Chon NR, Park H. The effects of probiotics on symptoms of irritable bowel syndrome. Korean J Gastroenterol 2006;47:413-419.

46. Long ZR, Yu CH, Yang Y, Wang HN, Chi XX. [Clinical observation on acupuncture combined with microorganism pharmaceutical preparations for treatment of irritable bowel syndrome of constitution type]. Zhongguo Zhen Jiu 2006;26:403-405. [Chinese]

47. D’haens GR, Kovacs G, Vergauwe P, et al. A randomized controlled trial of the probiotic combination Lactibiane (R) in irritable bowel syndrome, the Lactibiane (R) study group. Gastroenterology 2007;132(suppl 2):A371.

48. Simren M, Ohman L, Olsson J, et al. Clinical trial: the effects of a fermented milk containing three probiotic bacteria in patients with irritable bowel syndrome—a randomized, double-blind, controlled study. Aliment Pharmacol Ther 2010;31:218-227.

49. Bauserman M, Michail S. The use of Lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J Pediatr 2005;147:197-201.

50. Gawronska A, Dzieczcziarz P, Horvath A, Szajewska H. A randomized, double-blind placebo-controlled trial of Lactibiane GG for abdominal pain disorders in children. Aliment Pharmacol Ther 2007;25:177-184.

51. Tsuchiya J, Barroto R, Okura K, Kawakita S, Fesce E, Marotta F. Single-blind follow-up study on the effectiveness of a symbiotic preparation in irritable bowel syndrome. Chin J Dig Dis 2004;5:169-174.

52. Ligiarden SC, Axelsson L, Naterstad K, Lydersen S, Farup PG. A candidate probiotic with unfavourable effects in subjects with irritable bowel syndrome: a randomised controlled trial. BMJ Gastroenterol 2010;10:16.

53. Maupas JL, Champemont P, Delforge M. Treatment of irritable bowel syndrome. Double blind trial of Saccharomyces boulardii. Med Chir Dig 1983;12:77-79.

54. Delforge M, Maupas JL, Champemont P. [Treatment of functional colopathies: double-blind trial with perenterol]. Rev Med Liege 1983;38:883-888. [French]

55. Thompson WG, Dotevall G, Drossman DA, Heaton KW, Kruis W. Irritable bowel syndrome: guidelines for the diagnosis. Gastroenterol Int 1989;2:92-95.

56. Halpern GM, Prindiville T, Blankenburg M, Hiaa T, Gershwin ME. Treatment of irritable bowel syndrome with Lactel Fort: a randomized, double-blind, cross-over trial. Am J Gastroenterol 1996;91:1579-1585.

57. Shavalkhi A, Minakari M, Farzannia S, et al. The effects of multi-strain probiotic compound on symptoms and quality-of-life in patients with irritable bowel syndrome: a randomized placebo-controlled trial. Adv Biomed Res 2014;3:140.

58. Jafari E, Vahedi H, Merat S, Montahen S, Riahi A. Therapeutic effects, tolerability and safety of a multi-strain probiotic in Iranian adults with irritable bowel syndrome and bloating. Arch Iran Med 2014;17:466-470.

59. Lorenzo-Zúñiga V, Lloyd N, Sáiz C, et al. L.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life. World J Gastroenterol 2014;20:8709-8716.

60. Sisson G, Aysis S, Sherwood RA, Bjarnason I. Randomised clinical trial: A liquid multi-strain probiotic vs. placebo in the irritable bowel syndrome—a 12 week double-blind study. Aliment Pharmacol Ther 2014;40:51-62.
61. Ludivi S, Jonkman DM, Koning CJ, et al. Randomized clinical trial on the effect of a multispecies probiotic on viscerosensory perception in hypersecretive IBS patients. Neurogastroenterology Motil 2014;26:705-714.

62. Ko SJ, Han G, Kim SK, et al. Effect of Korean herbal medicine combined with a probiotic mixture on diarrhea-dominant irritable bowel syndrome: a double-blind, randomized, placebo-controlled trial. Evid Based Complement Alternat Med 2013;2013:824605.

63. Begtrup LM, de Muckadell OB, Bjeldsen J, Christensen RD, Jarbol DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome—a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013;48:1127-1135.

64. Yoon JS, Sohn W, Lee OY, et al. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol 2014;29:52-59.

65. Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. BMC Gastroenterol 2013;13:45.

66. Min YW, Park SU, Jang YS, et al. Effect of composite yogurt enriched with acacia fiber and Bifidobacterium lactis. World J Gastroenterol 2012;18:4563-4569.

67. Cappello C, Tremolaterra F, Pascariello A, Ciacci C, Iovino P. A randomised clinical trial of a symbiotic mixture in patients with irritable bowel syndrome (IBS): effects on symptoms, colonic transit and quality of life. Int J Colorectal Dis 2013;28:349-358.

68. Ki Cha B, Mun Jung S, Hwan Chou C, et al. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Clin Gastroenterol 2012;46:220-227.

69. Michail S, Kenche H. Gut microbiota is not modified by randomised, double-blind, placebo-controlled trial of VSL#3 in diarrhea-predominant irritable bowel syndrome. Probiotics Antimicrob Proteins 2011;3:1-7.

70. Hong YS, Hong KS, Park MH, et al. Metabonomic understanding of probiotic effects in humans with irritable bowel syndrome. J Clin Gastroenterol 2011;45:615-625.

71. Sondergaard B, Olsson J, Ohlson K, Svensson U, Bytzer P, Eldebo R. Effects of probiotic fermented milk on symptoms and intestinal flora in patients with irritable bowel syndrome: a randomized, placebo-controlled trial. Scand J Gastroenterol 2011;46:663-672.

72. Ringel-Kulka T, Palsson OS, Maier D, et al. Probiotic bacteria Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 versus placebo for the bloating of patients in functional bowel disorders: a double-blind study. J Clin Gastroenterol 2011;45:518-525.

73. Williams EA, Stimpson J, Wang D, et al. Clinical trial: a multistrain probiotic preparation significantly reduces symptoms of irritable bowel syndrome in a double-blind placebo-controlled study. Aliment Pharmacol Ther 2009;29:97-103.

74. Kajander K, Mylläräinen E, Rajilić-Stojanović M, et al. Clinical trial: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota. Aliment Pharmacol Ther 2008;27:48-57.

75. Drouault-Holowacz S, Bieuevet S, Burckel A, Cazaubiel M, Dray X, Marteu P. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome. Gastroenterol Clin Biol 2008;32:147-152.

76. Kajander K, Hatakka K, Poussa T, Farkkila M, Korpela R. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 2005;22:387-394.

77. Kim HJ, Vuazquez Roque Mi, Camilleri M, et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 2005;17:687-696.

78. Bittner AC, Croffut RM, Strahan MC. Prescript-Assist probiotic-prebiotic treatment for irritable bowel syndrome: a methodologically oriented, 2-week, randomized, placebo-controlled, double-blind clinical study. Clin Ther 2005;27:735-761.

79. Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004;38:S104-S106.

80. Kim HJ, Camilleri M, McKinzie S, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003;17:895-904.

81. Riveros C, Dechartres A, Perrodeau E, Haneef R, Bouton I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med 2013;10:e1001566; discussion e1001566.

82. Becker JE, Krumholz HM, Ben-Josef G, Ross JS. Reporting of results in ClinicalTrials.gov and high-impact journals. JAMA 2014;313:1063-1065.

83. Pinetont de Chambrun G, Neut C, Chau A, et al. A randomized clinical trial of Saccharomyces cerevisiae versus placebo in the irritable bowel syndrome. Dig Liver Dis 2015;47:119-124.

84. Abbas Z, Yakoob J, Jaffi W, et al. Cytokine and clinical response to Saccharomyces boulardii therapy in diarrhea-dominant irritable bowel syndrome: a randomized trial. Eur J Gastroenterol Hepatol 2014;26:630-639.

85. Stevenson C, Blauw R, Fredericks E, Visser J, Roux S. Randomized clinical trial: effect of Lactobacillus plantarum 299v on symptoms of irritable bowel syndrome. Nutrition 2014;30:1151-1157.

86. Rogha M, Esfahani MZ, Zargarzadeh AH. The efficacy of a symbiotic containing Bacillus coagulans in treatment of irritable bowel syndrome: a randomized placebo-controlled trial. Gastroenterol Hepatol Bed Bench 2014;7:156-163.

87. Urgesi R, Casale C, Pistelli R, Rapaccini GL, de Vitis I. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox(R)) in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2012;36:206-215.

88. Charrbonneau D, Gibb RD, Quigley EM. Fecal excretion of Bifidobacterium infantis 35624 and changes in fecal microbiota after eight weeks of oral supplementation with encapsulated probiotic. Gut Microbes 2013;4:201-206.

89. Ducrotte P, Sawant P, Jayanthi V. Clinical trial: a randomised double-blind, placebo-controlled clinical trial: effect of Bifidobacterium lactis Bb-12 and Lactobacillus acidophilus NCFM on irritable bowel syndrome (IBS). World J Gastroenterol 2012;18:4012-4018.

90. Murakami K, Habsukawa C, Nobata Y, Moriguchi N, Takemura T. The effect of Lactobacillus brevis KB290 against irritable bowel syndrome.
Probiotics in IBS

syndrome: a placebo-controlled double-blind crossover trial. Biopysch Soc Med 2012;6:16.

91. Dapoigny M, Piche T, Ducotte P, Lanaud B, Cardot JM, Bernalier-Donadille A. Efficacy and safety profile of LCR35 complete freeze-dried culture in irritable bowel syndrome: a randomized, double-blind study. World J Gastroenterol 2012;18:2067-2075.

92. Kruis W, Chrabasik S, Boehm S, Stange C, Schulze J. A double-blind placebo-controlled trial to study therapeutic effects of probiotic Escherichia coli Nissle 1917 in subgroups of patients with irritable bowel syndrome. Int J Colorectal Dis 2012;27:467-474.

93. Kabir MA, Ishaque SM, Ali MS, Mahmuduzzaman M, Hasan M. Role of Saccharomyces boulardii in diarrhea predominant irritable bowel syndrome. Mymensingh Med J 2011;20:397-401.

94. Guglielmetti S, Mora D, Gschwendner M, Popp K. Randomised clinical trial: Bifidobacterium bifidum MINIB673 significantly alleviates irritable bowel syndrome and improves quality of life—a double-blind, placebo-controlled study. Aliment Pharmacol Ther 2011;33:1123-1132.

95. Choi CH, Jo SY, Park HJ, Chang SK, Byeon JS, Myung SJ. A randomized, double-blind, placebo-controlled multicenter trial of Saccharomyces boulardii in irritable bowel syndrome: effect on quality of life. J Clin Gastroenterol 2011;45:679-683.

96. Dolin BJ. Effects of a proprietary Bacillus coagulans preparation on symptoms of diarrhea-predominant irritable bowel syndrome. Methods Find Exp Clin Pharmacol 2009;31:653-659.

97. Hun L. Bacillus coagulans significantly improved abdominal pain and bloating in patients with IBS. Postgrad Med 2009;121:119-124.

98. Enck P, Zimmermann K, Menke G, Klosterhalfen S. Randomized controlled treatment trial of irritable bowel syndrome with a probiotic E. coli preparation (DSM17252) compared to placebo. Z Gastroenterol 2009;47:209-214.

99. Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2009;29:104-114.

100. Sinn DH, Song JH, Kim HJ, et al. Therapeutic effect of Lactobacillus acidophilus-SCD 2012, 2013 in patients with irritable bowel syndrome. Dig Dis Sci 2008;53:2714-2718.

101. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 2007;26:475-486.

102. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 2006;101:1581-1590.

103. Niv E, Naftali T, Hallak R, Vaisman N. The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome—a double blind, placebo-controlled, randomized study. Clin Nutr 2005;24:925-931.

104. O’Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551.

105. Sen S, Mullan MM, Parker TJ, Woolner JT, Tarry SA, Hunter JO. Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome. Dig Dis Sci 2002;47:2615-2620.

106. Niedzielin K, Kordecki H, Birkenfeld B. A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299v in patients with irritable bowel syndrome. Eur J Gastroenterol Hepatol 2001;13:1143-1147.

107. O’Sullivan MA, O’Morain CA. Bacterial supplementation in the irritable bowel syndrome. A randomized double-blind placebo-controlled crossover study. Dig Liver Dis 2000;32:294-301.

108. Nobeck S, Johansson ML, Molin G, Ahme S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-1238.

109. Weimer K, Enck P. Traditional and innovative experimental and clinical trial designs and their advantages and pitfalls. Handb Exp Pharmacol 2014;225:237-272.

110. Schwille-Kiuntke J, Frick JS, Zanger P, Enck P. Post-infectious irritable bowel syndrome—a review of the literature. Z Gastroenterol 2011;49:997-1003.

111. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011;17:252-266.

112. Guidance for Industry. Irritable bowel syndrome—clinical evaluation of drugs for treatment: Food and Drug Administration (FDA), Center for Drug Evaluation and Research, May 2012.

113. Guideline on the evaluation of medicinal products for the treatment of irritable bowel syndrome. CPMP/EWP/785/97 Rev. 1: European Medicines Agency (EMA), Committee for Medicinal Products for Human use, Sept 2014.

114. Eisenbruch S, Enck P. Placebo effects and their determinants in gastrointestinal disorders. Nat Rev Gastroenterol Hepatol 2015;12:472-485.

115. Memorandum of understanding of working arrangements: European Medicines Agency (EMA), European Food Safety Authority, January 2012.

116. Yao CK, Gibson PR, Shepherd SJ. Design of clinical trials evaluating dietary interventions in patients with functional gastrointestinal disorders. Am J Gastroenterol 2013;108:748-758.

117. Colloca L. Placebo, nocebo, and learning mechanisms. Handb Exp Pharmacol 2014;225:17-35.

118. Dubois RW. Looking at CER from the pharmaceutical industry perspective. J Manag Care Pharm 2012;18(suppl A):S9-S12.